Autophagy in acute leukemias: A double-edged sword with important therapeutic implications

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1853, Issue 1, 2015, Pages 14-26

  Evangelisti, Cecilia ^a   Evangelisti, Camilla ^b   Chiarini, Francesca ^b   Lonetti, Annalisa ^a   Buontempo, Francesca ^a   Neri, Luca M ^c   McCubrey, James A ^d   Martelli, Alberto M ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^c UNIVERSITY OF FERRARA   (Italy)

^d EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Acute leukemia; Autophagy; Cell death; Cell survival; Hematopoietic stem cell; Targeted therapy

Indexed keywords

4 (4 AMINO 5 (7 METHOXY 1H INDOL 2 YL)IMIDAZO[5,1 F][1,2,4]TRIAZIN 7 YL)CYCLOHEXANECARBOXYLIC ACID; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; ASPARAGINASE; AZACITIDINE; AZD 2014; AZD 8055; BAFILOMYCIN A1; CHLOROQUINE; CYTARABINE; DAPORINAD; DEXAMETHASONE; EVEROLIMUS; FINGOLIMOD; HYDROXYCHLOROQUINE; IDARUBICIN; METFORMIN; MOCETINOSTAT; OBATOCLAX; PROTEIN; RAPAMYCIN; RETINOIC ACID; SORAFENIB; TEMSIROLIMUS; TRICHOSTATIN A; TRICIRIBINE; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; AUTOPHAGY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER INHIBITION; CANCER PATIENT; CANCER PROGNOSIS; CELL DIFFERENTIATION; CELL FUNCTION; CELL PROTECTION; CELL SURVIVAL; CELL VIABILITY; CYTOTOXICITY; EXPERIMENTAL THERAPY; HEMATOLOGIC MALIGNANCY; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; IN VITRO STUDY; MITOPHAGY; MOLECULAR MECHANICS; NEOPLASM; NONHUMAN; OUTCOME ASSESSMENT; PROMYELOCYTIC LEUKEMIA; REVIEW; ACUTE DISEASE; LEUKEMIA; PATHOLOGY; PHYSIOLOGY;

ACUTE DISEASE; AUTOPHAGY; HEMATOPOIESIS; HUMANS; LEUKEMIA; LEUKEMIA, MYELOID, ACUTE; LEUKEMIA, PROMYELOCYTIC, ACUTE; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 84908192379     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2014.09.023     Document Type: Review

References (194)

1. Klionsky D.J., Cuervo A.M., Dunn W.A., Levine B., van der Klei I., Seglen P.O. How shall I eat thee?. Autophagy 2007, 3:413-416.
2. Li W.W., Li J., Bao J.K. Microautophagy: lesser-known self-eating. Cell. Mol. Life Sci. 2012, 69:1125-1136.
3. Cuervo A.M., Wong E. Chaperone-mediated autophagy: roles in disease and aging. Cell Res. 2014, 24:92-104.
4. Pyo J.O., Yoo S.M., Jung Y.K. The interplay between autophagy and aging. Diabetes Metab. J. 2013, 37:333-339.
5. Jin M., Klionsky D.J. Regulation of autophagy: modulation of the size and number of autophagosomes. FEBS Lett. 2014, 588:2457-2463.
6. Ma T., Zhu J., Chen X., Zha D., Singhal P.C., Ding G. High glucose induces autophagy in podocytes. Exp. Cell Res. 2013, 319:779-789.
7. Yang L., Zhao D., Ren J., Yang J. Endoplasmic reticulum stress and protein quality control in diabetic cardiomyopathy. Biochim. Biophys. Acta 2014, 10.1016/j.bbadis.2014.05.006.
8. Mei Y., Thompson M.D., Cohen R.A., Tong X. Autophagy and oxidative stress in cardiovascular diseases. Biochim. Biophys. Acta 2014, 10.1016/j.bbadis.2014.05.005.
9. Jia G., Sowers J.R. Autophagy: a housekeeper in cardiorenal metabolic health and disease. Biochim. Biophys. Acta 2014, 10.1016/j.bbadis.2014.06.025.
10. Green D.R., Levine B. To be or not to be? How selective autophagy and cell death govern cell fate. Cell 2014, 157:65-75.
11. Mizushima N., Komatsu M. Autophagy: renovation of cells and tissues. Cell 2011, 147:728-741.
12. Yang Z., Klionsky D.J. Eaten alive: a history of macroautophagy. Nat. Cell Biol. 2010, 12:814-822.
13. Levine B., Mizushima N., Virgin H.W. Autophagy in immunity and inflammation. Nature 2011, 469:323-335.
14. Winslow A.R., Rubinsztein D.C. Autophagy in neurodegeneration and development. Biochim. Biophys. Acta 2008, 1782:723-729.
15. Mizushima N., Levine B., Cuervo A.M., Klionsky D.J. Autophagy fights disease through cellular self-digestion. Nature 2008, 451:1069-1075.
16. Boya P., Reggiori F., Codogno P. Emerging regulation and functions of autophagy. Nat. Cell Biol. 2013, 15:713-720.
17. Ge L., Baskaran S., Schekman R., Hurley J.H. The protein-vesicle network of autophagy. Curr. Opin. Cell Biol. 2014, 29C:18-24.
18. Nagelkerke A., Sweep F.C., Geurts-Moespot A., Bussink J., Span P.N. Therapeutic targeting of autophagy in cancer. Part I: molecular pathways controlling autophagy. Semin. Cancer Biol. 2014, 10.1016/j.semcancer.2014.05.004.
19. Nakatogawa H., Suzuki K., Kamada Y., Ohsumi Y. Dynamics and diversity in autophagy mechanisms: lessons from yeast. Nat. Rev. Mol. Cell Biol. 2009, 10:458-467.
20. Denton D., Nicolson S., Kumar S. Cell death by autophagy: facts and apparent artefacts. Cell Death Differ. 2012, 19:87-95.
21. Levine B., Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008, 132:27-42.
22. Yang Z., Klionsky D.J. Mammalian autophagy: core molecular machinery and signaling regulation. Curr. Opin. Cell Biol. 2010, 22:124-131.
23. Memmott R.M., Dennis P.A. Akt-dependent and -independent mechanisms of mTOR regulation in cancer. Cell. Signal. 2009, 21:656-664.
24. Fingar D.C., Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 2004, 23:3151-3171.
25. Martini M., De Santis M.C., Braccini L., Gulluni F., Hirsch E. PI3K/AKT signaling pathway and cancer: an updated review. Ann. Med. 2014, 1-12.
26. Polivka J., Janku F. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol. Ther. 2014, 142:164-175.
27. Kelly K.R., Rowe J.H., Padmanabhan S., Nawrocki S.T., Carew J.S. Mammalian target of rapamycin as a target in hematological malignancies. Target. Oncol. 2011, 6:53-61.
28. Kim J., Kundu M., Viollet B., Guan K.L. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat. Cell Biol. 2011, 13:132-141.
29. Ganley I.G., Lam du H., Wang J., Ding X., Chen S., Jiang X. ULK1.ATG13.FIP200 complex mediates mTOR signaling and is essential for autophagy. J. Biol. Chem. 2009, 284:12297-12305.
30. Chan E.Y. Regulation and function of uncoordinated-51 like kinase proteins. Antioxid. Redox Signal. 2012, 17:775-785.
31. He C., Klionsky D.J. Regulation mechanisms and signaling pathways of autophagy. Annu. Rev. Genet. 2009, 43:67-93.
32. Bach M., Larance M., James D.E., Ramm G. The serine/threonine kinase ULK1 is a target of multiple phosphorylation events. Biochem. J. 2011, 440:283-291.
33. Alers S., Wesselborg S., Stork B. ATG13: just a companion, or an executor of the autophagic program?. Autophagy 2014, 10:944-956.
34. Jung C.H., Jun C.B., Ro S.H., Kim Y.M., Otto N.M., Cao J., Kundu M., Kim D.H. ULK-Atg13-FIP200 complexes mediate mTOR signaling to the autophagy machinery. Mol. Biol. Cell 2009, 20:1992-2003.
35. Kroemer G., Marino G., Levine B. Autophagy and the integrated stress response. Mol. Cell 2010, 40:280-293.
36. Dunlop E.A., Hunt D.K., Acosta-Jaquez H.A., Fingar D.C., Tee A.R. ULK1 inhibits mTORC1 signaling, promotes multisite Raptor phosphorylation and hinders substrate binding. Autophagy 2011, 7:737-747.
37. Martelli A.M., Chiarini F., Evangelisti C., Ognibene A., Bressanin D., Billi A.M., Manzoli L., Cappellini A., McCubrey J.A. Targeting the liver kinase B1/AMP-activated protein kinase pathway as a therapeutic strategy for hematological malignancies. Expert Opin. Ther. Targets 2012, 16:729-742.
38. Dunlop E.A., Tee A.R. The kinase triad, AMPK, mTORC1 and ULK1, maintains energy and nutrient homoeostasis. Biochem. Soc. Trans. 2013, 41:939-943.
39. Hailey D.W., Rambold A.S., Satpute-Krishnan P., Mitra K., Sougrat R., Kim P.K., Lippincott-Schwartz J. Mitochondria supply membranes for autophagosome biogenesis during starvation. Cell 2010, 141:656-667.
40. Ravikumar B., Moreau K., Jahreiss L., Puri C., Rubinsztein D.C. Plasma membrane contributes to the formation of pre-autophagosomal structures. Nat. Cell Biol. 2010, 12:747-757.
41. English L., Chemali M., Duron J., Rondeau C., Laplante A., Gingras D., Alexander D., Leib D., Norbury C., Lippe R., Desjardins M. Autophagy enhances the presentation of endogenous viral antigens on MHC class I molecules during HSV-1 infection. Nat. Immunol. 2009, 10:480-487.
42. He C., Levine B. The Beclin 1 interactome. Curr. Opin. Cell Biol. 2010, 22:140-149.
43. Abrahamsen H., Stenmark H., Platta H.W. Ubiquitination and phosphorylation of Beclin 1 and its binding partners: tuning class III phosphatidylinositol 3-kinase activity and tumor suppression. FEBS Lett. 2012, 586:1584-1591.
44. Pattingre S., Tassa A., Qu X., Garuti R., Liang X.H., Mizushima N., Packer M., Schneider M.D., Levine B. Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell 2005, 122:927-939.
45. Tanida I., Ueno T., Kominami E. LC3 conjugation system in mammalian autophagy. Int. J. Biochem. Cell Biol. 2004, 36:2503-2518.
46. Tanida I., Ueno T., Kominami E. Human light chain 3/MAP1LC3B is cleaved at its carboxyl-terminal Met121 to expose Gly120 for lipidation and targeting to autophagosomal membranes. J. Biol. Chem. 2004, 279:47704-47710.
47. Kraft C., Peter M., Hofmann K. Selective autophagy: ubiquitin-mediated recognition and beyond. Nat. Cell Biol. 2010, 12:836-841.
48. Walczak M., Martens S. Dissecting the role of the Atg12-Atg5-Atg16 complex during autophagosome formation. Autophagy 2013, 9:424-425.
49. Ravikumar B., Sarkar S., Davies J.E., Futter M., Garcia-Arencibia M., Green-Thompson Z.W., Jimenez-Sanchez M., Korolchuk V.I., Lichtenberg M., Luo S., Massey D.C., Menzies F.M., Moreau K., Narayanan U., Renna M., Siddiqi F.H., Underwood B.R., Winslow A.R., Rubinsztein D.C. Regulation of mammalian autophagy in physiology and pathophysiology. Physiol. Rev. 2010, 90:1383-1435.
50. Kim K.H., Lee M.S. Autophagy-a key player in cellular and body metabolism. Nat. Rev. Endocrinol. 2014, 10:322-337.
51. Orkin S.H., Zon L.I. Hematopoiesis: an evolving paradigm for stem cell biology. Cell 2008, 132:631-644.
52. Martelli A.M., Evangelisti C., Chiarini F., Grimaldi C., Cappellini A., Ognibene A., McCubrey J.A. The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in normal myelopoiesis and leukemogenesis. Biochim. Biophys. Acta 2010, 1803:991-1002.
53. Gezer D., Vukovic M., Soga T., Pollard P.J., Kranc K.R. Concise review: genetic dissection of hypoxia signaling pathways in normal and leukemic stem cells. Stem Cells 2014, 32:1390-1397.
54. Wilson A., Laurenti E., Oser G., van der Wath R.C., Blanco-Bose W., Jaworski M., Offner S., Dunant C.F., Eshkind L., Bockamp E., Lio P., Macdonald H.R., Trumpp A. Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair. Cell 2008, 135:1118-1129.
55. Eliasson P., Jonsson J.I. The hematopoietic stem cell niche: low in oxygen but a nice place to be. J. Cell. Physiol. 2010, 222:17-22.
56. Guan J.L., Simon A.K., Prescott M., Menendez J.A., Liu F., Wang F., Wang C., Wolvetang E., Vazquez-Martin A., Zhang J. Autophagy in stem cells. Autophagy 2013, 9:830-849.
57. Phadwal K., Watson A.S., Simon A.K. Tightrope act: autophagy in stem cell renewal, differentiation, proliferation, and aging. Cell. Mol. Life Sci. 2013, 70:89-103.
58. Pan H., Cai N., Li M., Liu G.H., Izpisua Belmonte J.C. Autophagic control of cell 'stemness'. EMBO Mol. Med. 2013, 5:327-331.
59. Mortensen M., Soilleux E.J., Djordjevic G., Tripp R., Lutteropp M., Sadighi-Akha E., Stranks A.J., Glanville J., Knight S., Jacobsen S.E., Kranc K.R., Simon A.K. The autophagy protein Atg7 is essential for hematopoietic stem cell maintenance. J. Exp. Med. 2011, 208:455-467.
60. Liu F., Lee J.Y., Wei H., Tanabe O., Engel J.D., Morrison S.J., Guan J.L. FIP200 is required for the cell-autonomous maintenance of fetal hematopoietic stem cells. Blood 2010, 116:4806-4814.
61. Joshi A., Kundu M. Mitophagy in hematopoietic stem cells: the case for exploration. Autophagy 2013, 9:1737-1749.
62. Tothova Z., Kollipara R., Huntly B.J., Lee B.H., Castrillon D.H., Cullen D.E., McDowell E.P., Lazo-Kallanian S., Williams I.R., Sears C., Armstrong S.A., Passegue E., DePinho R.A., Gilliland D.G. FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell 2007, 128:325-339.
63. Gan B., Sahin E., Jiang S., Sanchez-Aguilera A., Scott K.L., Chin L., Williams D.A., Kwiatkowski D.J., DePinho R.A. mTORC1-dependent and -independent regulation of stem cell renewal, differentiation, and mobilization. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:19384-19389.
64. Simsek T., Kocabas F., Zheng J., Deberardinis R.J., Mahmoud A.I., Olson E.N., Schneider J.W., Zhang C.C., Sadek H.A. The distinct metabolic profile of hematopoietic stem cells reflects their location in a hypoxic niche. Cell Stem Cell 2010, 7:380-390.
65. Warr M.R., Binnewies M., Flach J., Reynaud D., Garg T., Malhotra R., Debnath J., Passegue E. FOXO3A directs a protective autophagy program in haematopoietic stem cells. Nature 2013, 494:323-327.
66. van der Vos K.E., Gomez-Puerto C., Coffer P.J. Regulation of autophagy by Forkhead box (FOX) O transcription factors. Adv. Biol. Regul. 2012, 52:122-136.
67. Lee J.H., Budanov A.V., Park E.J., Birse R., Kim T.E., Perkins G.A., Ocorr K., Ellisman M.H., Bodmer R., Bier E., Karin M. Sestrin as a feedback inhibitor of TOR that prevents age-related pathologies. Science 2010, 327:1223-1228.
68. Miyamoto K., Araki K.Y., Naka K., Arai F., Takubo K., Yamazaki S., Matsuoka S., Miyamoto T., Ito K., Ohmura M., Chen C., Hosokawa K., Nakauchi H., Nakayama K., Nakayama K.I., Harada M., Motoyama N., Suda T., Hirao A. Foxo3a is essential for maintenance of the hematopoietic stem cell pool. Cell Stem Cell 2007, 1:101-112.
69. Miyamoto K., Miyamoto T., Kato R., Yoshimura A., Motoyama N., Suda T. FoxO3a regulates hematopoietic homeostasis through a negative feedback pathway in conditions of stress or aging. Blood 2008, 112:4485-4493.
70. Salemi S., Yousefi S., Constantinescu M.A., Fey M.F., Simon H.U. Autophagy is required for self-renewal and differentiation of adult human stem cells. Cell Res. 2012, 22:432-435.
71. Heynen M.J., Tricot G., Verwilghen R.L. Autophagy of mitochondria in rat bone marrow erythroid cells. Cell Tissue Res. 1985, 239:235-239.
72. Mortensen M., Ferguson D.J., Edelmann M., Kessler B., Morten K.J., Komatsu M., Simon A.K. Loss of autophagy in erythroid cells leads to defective removal of mitochondria and severe anemia in vivo. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:832-837.
73. Betin V.M., Singleton B.K., Parsons S.F., Anstee D.J., Lane J.D. Autophagy facilitates organelle clearance during differentiation of human erythroblasts: evidence for a role for ATG4 paralogs during autophagosome maturation. Autophagy 2013, 9:881-893.
74. Kang Y.A., Sanalkumar R., O'Geen H., Linnemann A.K., Chang C.J., Bouhassira E.E., Farnham P.J., Keles S., Bresnick E.H. Autophagy driven by a master regulator of hematopoiesis. Mol. Cell. Biol. 2012, 32:226-239.
75. Schweers R.L., Zhang J., Randall M.S., Loyd M.R., Li W., Dorsey F.C., Kundu M., Opferman J.T., Cleveland J.L., Miller J.L., Ney P.A. NIX is required for programmed mitochondrial clearance during reticulocyte maturation. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:19500-19505.
76. Pua H.H., Dzhagalov I., Chuck M., Mizushima N., He Y.W. A critical role for the autophagy gene Atg5 in T cell survival and proliferation. J. Exp. Med. 2007, 204:25-31.
77. Stephenson L.M., Miller B.C., Ng A., Eisenberg J., Zhao Z., Cadwell K., Graham D.B., Mizushima N.N., Xavier R., Virgin H.W., Swat W. Identification of Atg5-dependent transcriptional changes and increases in mitochondrial mass in Atg5-deficient T lymphocytes. Autophagy 2009, 5:625-635.
78. Pua H.H., Guo J., Komatsu M., He Y.W. Autophagy is essential for mitochondrial clearance in mature T lymphocytes. J. Immunol. 2009, 182:4046-4055.
79. Farfariello V., Amantini C., Santoni G. Transient receptor potential vanilloid 1 activation induces autophagy in thymocytes through ROS-regulated AMPK and Atg4C pathways. J. Leukoc. Biol. 2012, 92:421-431.
80. Arsov I., Adebayo A., Kucerova-Levisohn M., Haye J., MacNeil M., Papavasiliou F.N., Yue Z., Ortiz B.D. A role for autophagic protein beclin 1 early in lymphocyte development. J. Immunol. 2011, 186:2201-2209.
81. Miller B.C., Zhao Z., Stephenson L.M., Cadwell K., Pua H.H., Lee H.K., Mizushima N.N., Iwasaki A., He Y.W., Swat W., Virgin H.W.t. The autophagy gene ATG5 plays an essential role in B lymphocyte development. Autophagy 2008, 4:309-314.
82. White E., DiPaola R.S. The double-edged sword of autophagy modulation in cancer. Clin. Cancer Res. 2009, 15:5308-5316.
83. Mathew R., Kongara S., Beaudoin B., Karp C.M., Bray K., Degenhardt K., Chen G., Jin S., White E. Autophagy suppresses tumor progression by limiting chromosomal instability. Genes Dev. 2007, 21:1367-1381.
84. Mathew R., Karp C.M., Beaudoin B., Vuong N., Chen G., Chen H.Y., Bray K., Reddy A., Bhanot G., Gelinas C., Dipaola R.S., Karantza-Wadsworth V., White E. Autophagy suppresses tumorigenesis through elimination of p62. Cell 2009, 137:1062-1075.
85. Thorburn A., Thamm D.H., Gustafson D.L. Autophagy and cancer therapy. Mol. Pharmacol. 2014, 85:830-838.
86. Morselli E., Galluzzi L., Kepp O., Vicencio J.M., Criollo A., Maiuri M.C., Kroemer G. Anti- and pro-tumor functions of autophagy. Biochim. Biophys. Acta 2009, 1793:1524-1532.
87. Roy S., Debnath J. Autophagy and tumorigenesis. Semin. Immunopathol. 2010, 32:383-396.
88. Dalby K.N., Tekedereli I., Lopez-Berestein G., Ozpolat B. Targeting the prodeath and prosurvival functions of autophagy as novel therapeutic strategies in cancer. Autophagy 2010, 6:322-329.
89. Nagelkerke A., Bussink J., Geurts-Moespot A., Sweep F.C., Span P.N. Therapeutic targeting of autophagy in cancer. Part II: pharmacological modulation of treatment-induced autophagy. Semin. Cancer Biol. 2014, 10.1016/j.semcancer.2014.06.001.
90. Poklepovic A., Gewirtz D.A. Outcome of early clinical trials of the combination of hydroxychloroquine with chemotherapy in cancer. Autophagy 2014, 10:1478-1480.
91. Vogl D.T., Stadtmauer E.A., Tan K.S., Heitjan D.F., Davis L.E., Pontiggia L., Rangwala R., Piao S., Chang Y.C., Scott E.C., Paul T.M., Nichols C.W., Porter D.L., Kaplan J., Mallon G., Bradner J.E., Amaravadi R.K. Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma. Autophagy 2014, 10:1380-1390.
92. Macintosh R.L., Ryan K.M. Autophagy in tumour cell death. Semin. Cancer Biol. 2013, 23:344-351.
93. Pullarkat V., Meng Z., Donohue C., Yamamoto V.N., Tomassetti S., Bhatia R., Krishnan A., Forman S.J., Synold T.W. Iron chelators induce autophagic cell death in multiple myeloma cells. Leuk. Res. 2014, 10.1016/j.leukres.2014.06.005.
94. Ristic B., Bosnjak M., Arsikin K., Mircic A., Suzin-Zivkovic V., Bogdanovic A., Perovic V., Martinovic T., Kravic-Stevovic T., Bumbasirevic V., Trajkovic V., Harhaji-Trajkovic L. Idarubicin induces mTOR-dependent cytotoxic autophagy in leukemic cells. Exp. Cell Res. 2014, 326:90-102.
95. He W., Wang Q., Srinivasan B., Xu J., Padilla M.T., Li Z., Wang X., Liu Y., Gou X., Shen H.M., Xing C., Lin Y. A JNK-mediated autophagy pathway that triggers c-IAP degradation and necroptosis for anticancer chemotherapy. Oncogene 2014, 33:3004-3013.
96. Galluzzi L., Kepp O., Krautwald S., Kroemer G., Linkermann A. Molecular mechanisms of regulated necrosis. Semin. Cell Dev. Biol. 2014, 10.1016/j.semcdb.2014.02.006.
97. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 2010, 60:277-300.
98. Dores G.M., Devesa S.S., Curtis R.E., Linet M.S., Morton L.M. Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007. Blood 2012, 119:34-43.
99. Liersch R., Muller-Tidow C., Berdel W.E., Krug U. Prognostic factors for acute myeloid leukaemia in adults-biological significance and clinical use. Br. J. Haematol. 2014, 165:17-38.
100. Grimwade D., Walker H., Oliver F., Wheatley K., Harrison C., Harrison G., Rees J., Hann I., Stevens R., Burnett A., Goldstone A. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998, 92:2322-2333.
101. Slovak M.L., Kopecky K.J., Cassileth P.A., Harrington D.H., Theil K.S., Mohamed A., Paietta E., Willman C.L., Head D.R., Rowe J.M., Forman S.J., Appelbaum F.R. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000, 96:4075-4083.
102. Caceres-Cortes J.R. Blastic leukaemias (AML): a biologist's view. Cell Biochem. Biophys. 2013, 66:13-22.
103. Brandts C.H., Sargin B., Rode M., Biermann C., Lindtner B., Schwable J., Buerger H., Muller-Tidow C., Choudhary C., McMahon M., Berdel W.E., Serve H. Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation. Cancer Res. 2005, 65:9643-9650.
104. Gilliland D.G., Griffin J.D. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002, 100:1532-1542.
105. Falini B., Mecucci C., Tiacci E., Alcalay M., Rosati R., Pasqualucci L., La Starza R., Diverio D., Colombo E., Santucci A., Bigerna B., Pacini R., Pucciarini A., Liso A., Vignetti M., Fazi P., Meani N., Pettirossi V., Saglio G., Mandelli F., Lo-Coco F., Pelicci P.G., Martelli M.F. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N. Engl. J. Med. 2005, 352:254-266.
106. Pabst T., Mueller B.U., Zhang P., Radomska H.S., Narravula S., Schnittger S., Behre G., Hiddemann W., Tenen D.G. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-α (C/EBPα), in acute myeloid leukemia. Nat. Genet. 2001, 27:263-270.
107. Li J. Myelodysplastic syndrome hematopoietic stem cell. Int. J. Cancer 2013, 133:525-533.
108. Troy J.D., Atallah E., Geyer J.T., Saber W. Myelodysplastic syndromes in the United States: an update for clinicians. Ann. Med. 2014, 46:283-289.
109. Farquhar M.J., Bowen D.T. Oxidative stress and the myelodysplastic syndromes. Int. J. Hematol. 2003, 77:342-350.
110. Houwerzijl E.J., Pol H.W., Blom N.R., van der Want J.J., de Wolf J.T., Vellenga E. Erythroid precursors from patients with low-risk myelodysplasia demonstrate ultrastructural features of enhanced autophagy of mitochondria. Leukemia 2009, 23:886-891.
111. Silva A., Yunes J.A., Cardoso B.A., Martins L.R., Jotta P.Y., Abecasis M., Nowill A.E., Leslie N.R., Cardoso A.A., Barata J.T. PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. J. Clin. Invest. 2008, 118:3762-3774.
112. Evangelisti C., Chiarini F., Lonetti A., Buontempo F., Bressanin D., Cappellini A., Orsini E., McCubrey J.A., Martelli A.M. Therapeutic potential of targeting mTOR in T-cell acute lymphoblastic leukemia. Int. J. Oncol. 2014, 45:909-918.
113. Nyakern M., Tazzari P.L., Finelli C., Bosi C., Follo M.Y., Grafone T., Piccaluga P.P., Martinelli G., Cocco L., Martelli A.M. Frequent elevation of Akt kinase phosphorylation in blood marrow and peripheral blood mononuclear cells from high-risk myelodysplastic syndrome patients. Leukemia 2006, 20:230-238.
114. Follo M.Y., Mongiorgi S., Bosi C., Cappellini A., Finelli C., Chiarini F., Papa V., Libra M., Martinelli G., Cocco L., Martelli A.M. The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation. Cancer Res. 2007, 67:4287-4294.
115. Zhang J., Grindley J.C., Yin T., Jayasinghe S., He X.C., Ross J.T., Haug J.S., Rupp D., Porter-Westpfahl K.S., Wiedemann L.M., Wu H., Li L. PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature 2006, 441:518-522.
116. Mills K.I., Kohlmann A., Williams P.M., Wieczorek L., Liu W.M., Li R., Wei W., Bowen D.T., Loeffler H., Hernandez J.M., Hofmann W.K., Haferlach T. Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndrome. Blood 2009, 114:1063-1072.
117. Pellagatti A., Cazzola M., Giagounidis A., Perry J., Malcovati L., Della Porta M.G., Jadersten M., Killick S., Verma A., Norbury C.J., Hellstrom-Lindberg E., Wainscoat J.S., Boultwood J. Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells. Leukemia 2010, 24:756-764.
118. Watson A.S., Mortensen M., Simon A.K. Autophagy in the pathogenesis of myelodysplastic syndrome and acute myeloid leukemia. Cell Cycle 2011, 10:1719-1725.
119. Krawczyk J., Keane N., Freeman C.L., Swords R., O'Dwyer M., Giles F.J. 5-Azacytidine for the treatment of myelodysplastic syndromes. Expert. Opin. Pharmacother. 2013, 14:1255-1268.
120. Cluzeau T., Robert G., Puissant A., Jean-Michel K., Cassuto J.P., Raynaud S., Auberger P. Azacitidine-resistant SKM1 myeloid cells are defective for AZA-induced mitochondrial apoptosis and autophagy. Cell Cycle 2011, 10:2339-2343.
121. Cluzeau T., Robert G., Jacquel A., Auberger P. How recent advances in high-risk myelodysplastic syndrome physiopathology may impact future treatments. Curr. Pharm. Des. 2013, 19:5362-5373.
122. Lamoureux F., Zoubeidi A. Dual inhibition of autophagy and the AKT pathway in prostate cancer. Autophagy 2013, 9:1119-1120.
123. Rangwala R., Chang Y.C., Hu J., Algazy K., Evans T., Fecher L., Schuchter L., Torigian D.A., Panosian J., Troxel A., Tan K.S., Heitjan D.F., Demichele A., Vaughn D., Redlinger M., Alavi A., Kaiser J., Pontiggia L., Davis L.E., O'Dwyer P.J., Amaravadi R.K. Combined mTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma. Autophagy 2014, 10:1391-1402.
124. Mahalingam D., Mita M., Sarantopoulos J., Wood L., Amaravadi R., Davis L.E., Mita A., Curiel T.J., Espitia C.M., Nawrocki S.T., Giles F.J., Carew J.S. Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors. Autophagy 2014, 10:1403-1414.
125. Tamburini J., Elie C., Bardet V., Chapuis N., Park S., Broet P., Cornillet-Lefebvre P., Lioure B., Ugo V., Blanchet O., Ifrah N., Witz F., Dreyfus F., Mayeux P., Lacombe C., Bouscary D. Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients. Blood 2007, 110:1025-1028.
126. Martelli A.M., Evangelisti C., Chiarini F., McCubrey J.A. The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. Oncotarget 2010, 1:89-103.
127. Chiarini F., Lonetti A., Teti G., Orsini E., Bressanin D., Cappellini A., Ricci F., Tazzari P.L., Ognibene A., Falconi M., Pagliaro P., Iacobucci I., Martinelli G., Amadori S., McCubrey J.A., Martelli A.M. A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia. Oncotarget 2012, 3:1615-1628.
128. Altman J.K., Szilard A., Goussetis D.J., Sassano A., Colamonici M., Gounaris E., Frankfurt O., Giles F.J., Eklund E.A., Beauchamp E.M., Platanias L.C. Autophagy is a survival mechanism of acute myelogenous leukemia precursors during dual mTORC2/mTORC1 targeting. Clin. Cancer Res. 2014, 20:2400-2409.
129. Willems L., Chapuis N., Puissant A., Maciel T.T., Green A.S., Jacque N., Vignon C., Park S., Guichard S., Herault O., Fricot A., Hermine O., Moura I.C., Auberger P., Ifrah N., Dreyfus F., Bonnet D., Lacombe C., Mayeux P., Bouscary D., Tamburini J. The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia. Leukemia 2012, 26:1195-1202.
130. Willems L., Jacque N., Jacquel A., Neveux N., Maciel T.T., Lambert M., Schmitt A., Poulain L., Green A.S., Uzunov M., Kosmider O., Radford-Weiss I., Moura I.C., Auberger P., Ifrah N., Bardet V., Chapuis N., Lacombe C., Mayeux P., Tamburini J., Bouscary D. Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia. Blood 2013, 122:3521-3532.
131. Samudio I., Konopleva M. Asparaginase unveils glutamine-addicted AML. Blood 2013, 122:3398-3400.
132. Rahmani M., Aust M.M., Attkisson E., Williams D.C., Ferreira-Gonzalez A., Grant S. Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process. Blood 2012, 119:6089-6098.
133. Wei Y., Kadia T., Tong W., Zhang M., Jia Y., Yang H., Hu Y., Tambaro F.P., Viallet J., O'Brien S., Garcia-Manero G. The combination of a histone deacetylase inhibitor with the Bcl-2 homology domain-3 mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy. Clin. Cancer Res. 2010, 16:3923-3932.
134. Torgersen M.L., Engedal N., Boe S.O., Hokland P., Simonsen A. Targeting autophagy potentiates the apoptotic effect of histone deacetylase inhibitors in t(8;21) AML cells. Blood 2013, 122:2467-2476.
135. Klusmann J.H., Creutzig U., Zimmermann M., Dworzak M., Jorch N., Langebrake C., Pekrun A., Macakova-Reinhardt K., Reinhardt D. Treatment and prognostic impact of transient leukemia in neonates with Down syndrome. Blood 2008, 111:2991-2998.
136. Stankov M.V., El Khatib M., Kumar Thakur B., Heitmann K., Panayotova-Dimitrova D., Schoening J., Bourquin J.P., Schweitzer N., Leverkus M., Welte K., Reinhardt D., Li Z., Orkin S.H., Behrens G.M., Klusmann J.H. Histone deacetylase inhibitors induce apoptosis in myeloid leukemia by suppressing autophagy. Leukemia 2014, 28:577-588.
137. Nahimana A., Attinger A., Aubry D., Greaney P., Ireson C., Thougaard A.V., Tjornelund J., Dawson K.M., Dupuis M., Duchosal M.A. The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies. Blood 2009, 113:3276-3286.
138. Palmeira dos Santos C., Pereira G.J., Barbosa C.M., Jurkiewicz A., Smaili S.S., Bincoletto C. Comparative study of autophagy inhibition by 3MA and CQ on Cytarabine-induced death of leukaemia cells. J. Cancer Res. Clin. Oncol. 2014, 140:909-920.
139. Liu L., Yang M., Kang R., Wang Z., Zhao Y., Yu Y., Xie M., Yin X., Livesey K.M., Lotze M.T., Tang D., Cao L. HMGB1-induced autophagy promotes chemotherapy resistance in leukemia cells. Leukemia 2011, 25:23-31.
140. Sun X., Tang D. HMGB1-dependent and -independent autophagy. Autophagy 2014, 10:1873-1876.
141. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., Sultan C. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br. J. Haematol. 1976, 33:451-458.
142. Rowley J.D. Identification of the constant chromosome regions involved in human hematologic malignant disease. Science 1982, 216:749-751.
143. de The H., Chomienne C., Lanotte M., Degos L., Dejean A. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature 1990, 347:558-561.
144. Chomienne C., Ballerini P., Balitrand N., Huang M.E., Krawice I., Castaigne S., Fenaux P., Tiollais P., Dejean A., Degos L., et al. The retinoic acid receptor α gene is rearranged in retinoic acid-sensitive promyelocytic leukemias. Leukemia 1990, 4:802-807.
145. Zeisig B.B., Kwok C., Zelent A., Shankaranarayanan P., Gronemeyer H., Dong S., So C.W. Recruitment of RXR by homotetrameric RARα fusion proteins is essential for transformation. Cancer Cell 2007, 12:36-51.
146. de The H., Chen Z. Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat. Rev. Cancer 2010, 10:775-783.
147. Faber J., Armstrong S.A. Mixed lineage leukemia translocations and a leukemia stem cell program. Cancer Res. 2007, 67:8425-8428.
148. Dos Santos G.A., Kats L., Pandolfi P.P. Synergy against PML-RARα: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia. J. Exp. Med. 2013, 210:2793-2802.
149. 3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:5328-5335.
150. Lo-Coco F., Avvisati G., Vignetti M., Thiede C., Orlando S.M., Iacobelli S., Ferrara F., Fazi P., Cicconi L., Di Bona E., Specchia G., Sica S., Divona M., Levis A., Fiedler W., Cerqui E., Breccia M., Fioritoni G., Salih H.R., Cazzola M., Melillo L., Carella A.M., Brandts C.H., Morra E., von Lilienfeld-Toal M., Hertenstein B., Wattad M., Lubbert M., Hanel M., Schmitz N., Link H., Kropp M.G., Rambaldi A., La Nasa G., Luppi M., Ciceri F., Finizio O., Venditti A., Fabbiano F., Dohner K., Sauer M., Ganser A., Amadori S., Mandelli F., Dohner H., Ehninger G., Schlenk R.F., Platzbecker U. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N. Engl. J. Med. 2013, 369:111-121.
151. Orfali N., McKenna S.L., Cahill M.R., Gudas L.J., Mongan N.P. Retinoid receptor signaling and autophagy in acute promyelocytic leukemia. Exp. Cell Res. 2014, 324:1-12.
152. Nasr R., Guillemin M.C., Ferhi O., Soilihi H., Peres L., Berthier C., Rousselot P., Robledo-Sarmiento M., Lallemand-Breitenbach V., Gourmel B., Vitoux D., Pandolfi P.P., Rochette-Egly C., Zhu J., de The H. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nat. Med. 2008, 14:1333-1342.
153. Isakson P., Bjoras M., Boe S.O., Simonsen A. Autophagy contributes to therapy-induced degradation of the PML/RARA oncoprotein. Blood 2010, 116:2324-2331.
154. a oncoprotein. Autophagy 2011, 7:401-411.
155. Trocoli A., Mathieu J., Priault M., Reiffers J., Souquere S., Pierron G., Besancon F., Djavaheri-Mergny M. ATRA-induced upregulation of Beclin 1 prolongs the life span of differentiated acute promyelocytic leukemia cells. Autophagy 2011, 7:1108-1114.
156. a enhances constitutive autophagic activity through inhibiting the Akt/mTOR pathway. Autophagy 2011, 7:1132-1144.
157. Goussetis D.J., Gounaris E., Wu E.J., Vakana E., Sharma B., Bogyo M., Altman J.K., Platanias L.C. Autophagic degradation of the BCR-ABL oncoprotein and generation of antileukemic responses by arsenic trioxide. Blood 2012, 120:3555-3562.
158. Sinclair A., Latif A.L., Holyoake T.L. Targeting survival pathways in chronic myeloid leukaemia stem cells. Br. J. Pharmacol. 2013, 169:1693-1707.
159. Goussetis D.J., Altman J.K., Glaser H., McNeer J.L., Tallman M.S., Platanias L.C. Autophagy is a critical mechanism for the induction of the antileukemic effects of arsenic trioxide. J. Biol. Chem. 2010, 285:29989-29997.
160. Xie N., Zhong L., Liu L., Fang Y., Qi X., Cao J., Yang B., He Q., Ying M. Autophagy contributes to dasatinib-induced myeloid differentiation of human acute myeloid leukemia cells. Biochem. Pharmacol. 2014, 89:74-85.
161. Pui C.H., Mullighan C.G., Evans W.E., Relling M.V. Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?. Blood 2012, 120:1165-1174.
162. Inaba H., Greaves M., Mullighan C.G. Acute lymphoblastic leukaemia. Lancet 2013, 381:1943-1955.
163. Mullighan C.G. The molecular genetic makeup of acute lymphoblastic leukemia. Hematol. Am. Soc. Hematol. Educ. Program 2012, 2012:389-396.
164. Fuka G., Kauer M., Kofler R., Haas O.A., Panzer-Grumayer R. The leukemia-specific fusion gene ETV6/RUNX1 perturbs distinct key biological functions primarily by gene repression. PLoS One 2011, 6:e26348.
165. Badura S., Tesanovic T., Pfeifer H., Wystub S., Nijmeijer B.A., Liebermann M., Falkenburg J.H., Ruthardt M., Ottmann O.G. Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia. PLoS One 2013, 8:e80070.
166. Altman B.J., Jacobs S.R., Mason E.F., Michalek R.D., MacIntyre A.N., Coloff J.L., Ilkayeva O., Jia W., He Y.W., Rathmell J.C. Autophagy is essential to suppress cell stress and to allow BCR-Abl-mediated leukemogenesis. Oncogene 2011, 30:1855-1867.
167. Teuffel O., Kuster S.P., Hunger S.P., Conter V., Hitzler J., Ethier M.C., Shah P.S., Beyene J., Sung L. Dexamethasone versus prednisone for induction therapy in childhood acute lymphoblastic leukemia: a systematic review and meta-analysis. Leukemia 2011, 25:1232-1238.
168. Bhadri V.A., Trahair T.N., Lock R.B. Glucocorticoid resistance in paediatric acute lymphoblastic leukaemia. J. Paediatr. Child Health 2012, 48:634-640.
169. Laane E., Tamm K.P., Buentke E., Ito K., Kharaziha P., Oscarsson J., Corcoran M., Bjorklund A.C., Hultenby K., Lundin J., Heyman M., Soderhall S., Mazur J., Porwit A., Pandolfi P.P., Zhivotovsky B., Panaretakis T., Grander D. Cell death induced by dexamethasone in lymphoid leukemia is mediated through initiation of autophagy. Cell Death Differ. 2009, 16:1018-1029.
170. Heidari N., Hicks M.A., Harada H. GX15-070 (obatoclax) overcomes glucocorticoid resistance in acute lymphoblastic leukemia through induction of apoptosis and autophagy. Cell Death Dis. 2010, 1:e76.
171. Urtishak K.A., Edwards A.Y., Wang L.S., Hudome A., Robinson B.W., Barrett J.S., Cao K., Cory L., Moore J.S., Bantly A.D., Yu Q.C., Chen I.M., Atlas S.R., Willman C.L., Kundu M., Carroll A.J., Heerema N.A., Devidas M., Hilden J.M., Dreyer Z.E., Hunger S.P., Reaman G.H., Felix C.A. Potent obatoclax cytotoxicity and activation of triple death mode killing across infant acute lymphoblastic leukemia. Blood 2013, 121:2689-2703.
172. Neri L.M., Cani A., Martelli A.M., Simioni C., Junghanss C., Tabellini G., Ricci F., Tazzari P.L., Pagliaro P., McCubrey J.A., Capitani S. Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential. Leukemia 2014, 28:739-748.
173. Crazzolara R., Bendall L. Emerging treatments in acute lymphoblastic leukemia. Curr. Cancer Drug Targets 2009, 9:19-31.
174. Crazzolara R., Bradstock K.F., Bendall L.J. RAD001 (Everolimus) induces autophagy in acute lymphoblastic leukemia. Autophagy 2009, 5:727-728.
175. Baraz R., Cisterne A., Saunders P.O., Hewson J., Thien M., Weiss J., Basnett J., Bradstock K.F., Bendall L.J. mTOR inhibition by everolimus in childhood acute lymphoblastic leukemia induces caspase-independent cell death. PLoS One 2014, 9:e102494.
176. Wallington-Beddoe C.T., Hewson J., Bradstock K.F., Bendall L.J. FTY720 produces caspase-independent cell death of acute lymphoblastic leukemia cells. Autophagy 2011, 7:707-715.
177. Teuffel O., Leibundgut K., Lehrnbecher T., Alonzo T.A., Beyene J., Sung L. Anthracyclines during induction therapy in acute myeloid leukaemia: a systematic review and meta-analysis. Br. J. Haematol. 2013, 161:192-203.
178. Van der Meulen J., Van Roy N., Van Vlierberghe P., Speleman F. The epigenetic landscape of T-cell acute lymphoblastic leukemia. Int. J. Biochem. Cell Biol. 2014, 53:547-557.
179. Van Vlierberghe P., Ferrando A. The molecular basis of T cell acute lymphoblastic leukemia. J. Clin. Invest. 2012, 122:3398-3406.
180. Aifantis I., Raetz E., Buonamici S. Molecular pathogenesis of T-cell leukaemia and lymphoma. Nat. Rev. Immunol. 2008, 8:380-390.
181. Correia N.C., Durinck K., Leite A.P., Ongenaert M., Rondou P., Speleman F., Enguita F.J., Barata J.T. Novel TAL1 targets beyond protein-coding genes: identification of TAL1-regulated microRNAs in T-cell acute lymphoblastic leukemia. Leukemia 2013, 27:1603-1606.
182. Schotte D., Pieters R., Den Boer M.L. MicroRNAs in acute leukemia: from biological players to clinical contributors. Leukemia 2012, 26:1-12.
183. Jia L., Dourmashkin R.R., Allen P.D., Gray A.B., Newland A.C., Kelsey S.M. Inhibition of autophagy abrogates tumour necrosis factor α induced apoptosis in human T-lymphoblastic leukaemic cells. Br. J. Haematol. 1997, 98:673-685.
184. Chiarini F., Grimaldi C., Ricci F., Tazzari P.L., Evangelisti C., Ognibene A., Battistelli M., Falcieri E., Melchionda F., Pession A., Pagliaro P., McCubrey J.A., Martelli A.M. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia. Cancer Res. 2010, 70:8097-8107.
185. Evangelisti C., Ricci F., Tazzari P., Chiarini F., Battistelli M., Falcieri E., Ognibene A., Pagliaro P., Cocco L., McCubrey J.A., Martelli A.M. Preclinical testing of the Akt inhibitor triciribine in T-cell acute lymphoblastic leukemia. J. Cell. Physiol. 2011, 226:822-831.
186. Simioni C., Neri L.M., Tabellini G., Ricci F., Bressanin D., Chiarini F., Evangelisti C., Cani A., Tazzari P.L., Melchionda F., Pagliaro P., Pession A., McCubrey J.A., Capitani S., Martelli A.M. Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia. Leukemia 2012, 26:2336-2342.
187. Grimaldi C., Chiarini F., Tabellini G., Ricci F., Tazzari P.L., Battistelli M., Falcieri E., Bortul R., Melchionda F., Iacobucci I., Pagliaro P., Martinelli G., Pession A., Barata J.T., McCubrey J.A., Martelli A.M. AMP-dependent kinase/mammalian target of rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implications. Leukemia 2012, 26:91-100.
188. Holliday M.W., Cox S.B., Kang M.H., Maurer B.J. C22:0- and C24:0-dihydroceramides confer mixed cytotoxicity in T-cell acute lymphoblastic leukemia cell lines. PLoS One 2013, 8:e74768.
189. Jiang Q., Li F., Shi K., Wu P., An J., Yang Y., Xu C. ATF4 activation by the p38MAPK-eIF4E axis mediates apoptosis and autophagy induced by selenite in Jurkat cells. FEBS Lett. 2013, 587:2420-2429.
190. Bonapace L., Bornhauser B.C., Schmitz M., Cario G., Ziegler U., Niggli F.K., Schafer B.W., Schrappe M., Stanulla M., Bourquin J.P. Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance. J. Clin. Invest. 2010, 120:1310-1323.
191. Rosenfeld M.R., Ye X., Supko J.G., Desideri S., Grossman S.A., Brem S., Mikkelson T., Wang D., Chang Y.C., Hu J., McAfee Q., Fisher J., Troxel A., Piao S., Heitjan D.F., Tan K.S., Pontiggia L., O'Dwyer P.J., Davis L.E., Amaravadi R.K. A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme. Autophagy 2014, 10:1359-1368.
192. Rangwala R., Leone R., Chang Y.C., Fecher L., Schuchter L., Kramer A., Tan K.S., Heitjan D.F., Rodgers G., Gallagher M., Piao S., Troxel A., Evans T., Demichele A., Nathanson K.L., O'Dwyer P.J., Kaiser J., Pontiggia L., Davis L.E., Amaravadi R.K. Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma. Autophagy 2014, 10:1369-1379.
193. Konopleva M.Y., Walter R.B., Faderl S.H., Jabbour E.J., Zeng Z., Borthakur G., Huang X., Kadia T.M., Ruvolo P.P., Feliu J.B., Lu H., Debose L., Burger J.A., Andreeff M., Liu W., Baggerly K.A., Kornblau S.M., Doyle L.A., Estey E.H., Kantarjian H.M. Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia. Clin. Cancer Res. 2014, 20:2226-2235.
194. Amadori S., Stasi R., Martelli A.M., Venditti A., Meloni G., Pane F., Martinelli G., Lunghi M., Pagano L., Cilloni D., Rossetti E., Di Raimondo F., Fozza C., Annino L., Chiarini F., Ricci F., Ammatuna E., La Sala E., Fazi P., Vignetti M. Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-1107). Br. J. Haematol. 2012, 156:205-212.